Fulcrum Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$80,000
$0
$871
$759
Gross Profit
79,600
-479
363
259
EBITDA
52,892
-29,355
-27,484
-26,909
EBIT
52,492
-29,834
-27,992
-27,409
Net Income
55,409
-26,870
-24,756
-24,017
Net Change In Cash
80,000
0
871
759
Free Cash Flow
58,899
-25,312
-23,235
-22,971
Cash
86,702
39,949
25,563
30,080
Basic Shares
63,587
61,984
61,871
61,823

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$2,805
$6,342
$19,163
$8,823
Gross Profit
633
3,928
19,163
8,823
EBITDA
-108,492
-111,707
-78,539
-69,232
EBIT
-110,664
-114,121
-81,054
-71,611
Net Income
-97,335
-105,621
-78,332
-68,440
Net Change In Cash
2,805
6,342
19,163
8,823
Cost of Revenue
-314
-21,640
-39,661
Free Cash Flow
-91,473
-99,013
-80,191
-54,997
Cash
25,563
35,098
35,412
57,052
Basic Shares
61,310
44,991
35,361
25,354

Earnings Calls

Quarter EPS
2024-06-30
$0.87
2024-03-31
-$0.43
2023-12-31
-$0.40
2023-09-30
-$0.39